| Product Name | Composition | Packing | Classification | View Details |
|---|---|---|---|---|
Leading PCD Pharma Company for Ophthalmic Range
As a premier PCD pharma company for the ophthalmic range, Zenexa Healthcare is dedicated to addressing the growing global demand for high-quality eye care solutions. Our vision is simple: to provide accessible, sterile, and effective medications that treat a spectrum of ocular conditions, from common bacterial infections to chronic glaucoma management.
In an era of increased digital screen exposure and rising environmental pollutants, eye health has become a paramount concern. We bridge this gap by manufacturing a diverse portfolio of eye drops, ointments, and oral supplements formulated in WHO-GMP certified facilities. Our commitment to quality ensures that every drop meets stringent safety standards, providing doctors and patients with the reliability they deserve.
Lucrative PCD Pharma Franchise for Ophthalmic Range
Choosing the right partner is critical for business success in the pharmaceutical sector. Zenexa Healthcare offers a robust PCD pharma franchise for the ophthalmic range, designed to empower entrepreneurs and pharma professionals across India. By joining our network, you gain access to a "monopoly-based" business model, ensuring exclusive rights to operate in your designated territory without internal competition.
Our ophthalmic portfolio includes:
- Antibiotic & Anti-infective Drops: High-efficacy formulations like Moxifloxacin (MOXIZEN) to combat bacterial conjunctivitis.
- Anti-inflammatory & Steroid Combinations: Advanced solutions for post-operative care and severe inflammation.
- Lubricating Eye Drops: Premium artificial tears for dry eye syndrome and digital eye strain relief.
- Anti-Allergic Solutions: Fast-acting drops to treat seasonal allergies and redness.
- Glaucoma & IOP Management: Critical medications to control intraocular pressure and prevent vision loss.
Why Partner with Zenexa Healthcare?
When you opt for our ophthalmic products franchise, you are not just getting a product list; you are gaining a comprehensive support system. We provide:
- Marketing & Promotional Kits: Visual aids, MR bags, visiting cards, and product glossaries to help you establish a strong market presence.
- Affordable Investment: Start your venture with a reasonable capital requirement and scale as your business grows.
- Timely Logistics: Our robust supply chain ensures that your inventory is replenished promptly, preventing stock-outs.
- Premium Packaging: We utilise specialised dropper bottles and contamination-proof packaging to maintain the sterile integrity of our ophthalmic range.
Frequently Asked Questions (FAQs)
Q1: What certifications do Zenexa Healthcare’s ophthalmic products hold? All our eye care formulations are manufactured in WHO-GMP and ISO-certified units. We strictly adhere to DCGI guidelines to ensure that every product is safe, effective, and of international quality.
Q2: Is a drug license mandatory to start an ophthalmic PCD franchise? Yes, a valid Wholesale Drug License and GST registration are mandatory requirements to start a pharma franchise business in India. These documents ensure that your business operates within the legal framework of the pharmaceutical industry.
Q3: Does Zenexa Healthcare provide monopoly rights for the ophthalmic segment? Absolutely. We offer exclusive area-wise monopoly rights. This means that as our franchise partner, you will be the sole distributor of our ophthalmic range in your allocated district or territory, allowing you to build your brand without local competition.
Q4: What is the typical shelf life of your eye drops? Most of our ophthalmic drops have a shelf life ranging from 18 to 24 months. However, once a bottle is opened, it is generally recommended to be used within 30 days to maintain sterility.
Q5: How can I apply for an ophthalmic products PCD franchise? You can start by browsing our product list and identifying the formulations you wish to market. Contact us through our official website or call our support team to discuss territory availability and the initial investment process.
